CLAIM CARD
Within the corpus, notable tensions exist between sources reporting positive cardiovascular signals and those reporting null findings. Samuel 2025 and Wang 2025 both indicate beneficial effects of colchicine on recurrent vascular events, while Mohammadnia 2025b, Maes 2026, and Shchendrygina 2023 report null or non-significant results in their respective analyses. These disagreements likely reflect differences in population selection, outcome definitions, follow-up duration, and colchicine dosing (0.5 mg/day in most RCTs) rather than fundamental contradictions, as many comparisons involve different clinical contexts or subgroups.
Evidence grade: exploratory
Contradiction status: none
Publication: 873ff54a-3a1e-4c35-b4ff-b2bb5ab68649
Provenance: Derivation Web chain
Citation Support
source_1Mohammadnia 2025source_2Li 2025source_3Ammirati 2026source_4Pascart 2026source_5Broekhoven 2022